28 December 2022 | News
To address growing interest and opportunities for bioconjugate drugs globally
China-based GeneQuantum Healthcare (GQ) and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), have entered into a strategic collaboration for conjugation technology licensing and antibody drug conjugate (ADC) drug development.
According to the collaboration agreements, Wuxi XDC will actively promote GeneQuantum's proprietary iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms around the globe to empower innovative bioconjugate development and the commercial production for drug developers.
GeneQuantum will also develop multiple ADC drugs through collaboration with Wuxi XDC, and foresee accelerated product commercialization based on Wuxi XDC's leading ADC production platform and integrated CMC capability.
Dr Jimmy Lee, CEO of Wuxi XDC, said, "New and innovative ideas and technologies have emerged in the field of bioconjugate drugs represented by ADC, which has become a hot spot of investment and drug development."